Ildong Idience presents 1st interim results for Venadaparib

at ASCO GI

“The clinical data demonstrated the competitiveness of the PARP inhibitor 'Venadaparib' as a targeted anticancer therapy compared to existing treatments”

On the 22nd, Idience, the new drug development subsidiary of Ildong Pharmaceutical, announced that they have presented the research findings related to 'Venadaparib' at the 2024 ASCO Gastrointestinal Cancers Symposium held from the 18th to the 20th.

 

Venadaparib is a novel targeted anticancer candidate product with a mechanism focused on selective inhibition of ‘Poly ADP-ribose polymerase (PARP).’ Idience is currently engaged in clinical development efforts for various cancer types, including gastric cancer, breast cancer, ovarian cancer, and cancers with resistance to PARP inhibitors.

 

Idience participated in a poster session at the symposium where they shared interim results from the Phase 1 clinical study.

 

This study involved a combination therapy of Venadaparib and chemotherapy irinotecan in patients with gastric cancer undergoing third- or fourth-line treatments.

 

According to the presentation, in the evaluable patient group (11 patients) who received an appropriate dosage combination of Venadaparib and irinotecan, the objective response rate (ORR) was 36.4%, with a median progression-free survival (mPFS) of 5.6 months.

 

In the clinical trial, it was observed that among all the patients enrolled, the ORR was significantly higher at 60% in the subset of gastric cancer patients (5 patients) with homologous recombination deficiency (HRD), a marker for cancer treatment.

 

“Considering that Lonsurf (trifluridine/tipiracil), which is used as third-line standard treatment for metastatic gastric cancer, has shown ORR at 4% and mPFS of 2.0 months, the clinical result of Venadaparib is promising,” Idience staff stated.

 

Additionally, “Current Venadaparib study is particularly valuable because considering that human epidermal growth factor receptor 2 (HER2) expression is a marker for classifying HER2-positive gastric cancer and HER2-negative gastric cancer, Venadaparib efficacy was evaluated in patients with HER2-positive gastric cancer or HER2-negative gastric cancer, “ Idience staff emphasized.

 

Since the current study confirmed Venadaparib's competitiveness and novelty compared to existing treatments, the company plans to speed up its development process, aiming to receive approval for the clinical entry (Phase 2/3) next year.

 

Furthermore, the company intends to utilize the expedited assessment and approval system to accelerate its commercialization agenda.

 

Idience is one of the subsidiaries of Ildong Holdings, formerly Ildong Pharmaceuticals.

 

The company owns several pipelines related to anticancer drugs.

 

Currently, Idience operates businesses, including clinical development of new candidate drugs, which includes Venadaparib, license-out, and open innovations.